Cipla stock

CIPLA · NSE · INR

Compare Cipla
₹1,415.00Change from previous close: −0.25%Absolute change: −₹3.50

Close · November 20, 2026

Price history

−7.47% over the period

1 year: from ₹1,529.20 (November 20, 2025) to ₹1,415.00 (November 20, 2026), −7.47%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026₹1,415.00
October 30, 2026₹1,378.90
September 30, 2026₹1,346.00
August 31, 2026₹1,409.20
July 31, 2026₹1,473.20
June 30, 2026₹1,465.40
May 29, 2026₹1,401.00
April 30, 2026₹1,309.60
March 30, 2026₹1,224.20
February 27, 2026₹1,348.20
January 30, 2026₹1,324.00
December 31, 2025₹1,511.30
November 28, 2025₹1,531.30
November 20, 2025₹1,529.20

At a glance

  • The company

    Manufactures and distributes generic and branded pharmaceutical products, vaccines, and active ingredients across multiple therapeutic areas globally

  • Latest results

    Quarter to September 30, 2026 · EPS ₹10.85 (estimate ₹11.54)

TickerLandia's take on Cipla

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low₹1,165.70
52-wk high₹1,539.70

−8.10% from the 52-week high

Analysts · 36 analysts

Average target₹1,507.31+6.52% vs. price

Buy 22 · Hold 12 · Sell 2 · Buy

TickerLandia Fingerprint: Cipla

Compared with similar companies: very low risk and very high financial strength.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Cipla is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2026), Cipla's P/E today is 29.5, in line with the median of its last 10 fiscal years (27.6; between 22.1 and 47.4 from 2017 to 2026). Cipla's P/E (trailing 12 months): 39.5, +38% against the median of a group of 11 similar companies (28.7).

P/E compared with its history

Compared with 11 similar companies

Cipla's metrics compared with similar companies
MetricCiplaPosition in the groupBand
P/E (trailing 12 months)39.5Middle
Forward P/E22.7Middle
Operating margin13.0%Low
ROE8.3%Low
Debt/equity0.02Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Cipla. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

₹73.68B

Latest quarter · Q3 2026

Net income

₹8.78B

Latest quarter · Q3 2026

Quarterly net margin

11.9%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
₹1.14T
P/E
39.5
EPS
₹35.84
Volume
1.48M
Daily trading
€21.37M
Dividend yield
0.92%
Last ex-dividend on June 5, 2026

How Cipla is changing

All results
  • Revenue grew 7.8% a year on average over the last 5 years

  • Free cash flow equal to 69% of net income

  • Revenue has grown for 9 fiscal years in a row

Returns

Cipla returns with dividends

₹1,000 invested in Cipla 5 years ago, on November 22, 2021, would be worth ₹1,647 today with dividends reinvested: +64.68% in total, +10.50% per year. On price alone it would be ₹1,580 (+58.03%).

PeriodCipla₹1,000 becomes
1 month+7.69%₹1,077
6 months+1.11%₹1,011
Year to date−6.37%₹936
1 year−6.61%₹934
3 years+16.72%₹1,167
5 years+64.68%₹1,647
10 years+178.75%₹2,788

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Cipla: technical analysis

Cipla shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 15.8% below its all-time closing high (₹1,680.50, October 9, 2024).

Trend
No clear trend
RSI (14 sessions)
61
Between 30 and 70
vs 200-session average
+3.50%

Active signals

  • Death cross: the 50-session average has crossed below the 200-session average.

    since November 12, 2026

Support and resistance

Price areas where Cipla has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance₹1,532.83+8.33%3 touches, last on January 6, 2026
  2. Resistance₹1,482.67+4.78%7 touches, last on August 6, 2026
  3. Resistance₹1,424.80+0.69%3 touches, last on November 9, 2026
  4. Last price₹1,415.00
  5. Support₹1,365.50−3.50%2 touches, last on July 23, 2026
  6. Support₹1,347.82−4.75%5 touches, last on September 16, 2026
  7. Support₹1,312.30−7.26%2 touches, last on February 23, 2026

Volatility and risk

Volatility (60 sessions, annualised)
14.6%
Largest fall in the last year
−22.13%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Cipla: seasonality

Average monthly price change over 31 years

−1.5%Jan−1.3%Feb+3.3%Mar+3.1%Apr−1.2%May+2.6%Jun+4.5%Jul+4.0%Aug+3.3%Sep+0.9%Oct+1.9%Nov+2.2%Dec

Over the last 31 years, the strongest month for Cipla has been July: +4.51% on average, positive in 22 years out of 31. The weakest has been January: −1.53% on average, positive in 11 years out of 30. November, the current month, has been positive in 14 years out of 30 (+1.87% on average).

Show chart data
MonthAverageMedianPositive years
January−1.53%−2.12%11 of 30
February−1.31%−2.11%10 of 31
March+3.32%+2.09%19 of 31
April+3.08%+3.24%20 of 31
May−1.21%−1.09%13 of 31
June+2.63%+2.74%21 of 31
July+4.51%+4.22%22 of 31
August+4.02%+3.02%21 of 31
September+3.29%+2.11%19 of 31
October+0.93%−0.19%14 of 31
November+1.87%−0.28%14 of 30
December+2.19%+1.55%18 of 30

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Cipla and its competitors

Customers in India, the United States and South Africa, along with buyers in other countries, are the markets this Mumbai-based drugmaker serves. Its products include off-patent medicines sold as generics and under its own brand names, alongside vaccines and the active ingredients used to make finished drugs. The range covers treatments for respiratory conditions, HIV/AIDS, heart and kidney disease, diabetes, oncology, child health and critical care, and the company also runs consumer healthcare, biosimilars and specialty businesses.

Headquarters
Mumbai, India
Employees
31,369
Founded
1935
Chief executive
Achin Gupta
Cipla and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
CiplaCIPLA$12.34B13.0%39.5+1.11%
Zhejiang NHU002001$11.61B33.8%10.6−19.16%
Zydus LifesciencesZYDUSLIFE$12.92B17.2%28.7+15.29%
Laurus LabsLAURUSLABS$14.13B24.1%97.8+68.58%
Yunnan Baiyao Group000538$15.07B11.2%19.4+11.07%
PharmaEssentia6446$15.94B38.4%74.1+54.65%

Same industry or related industries, similar size. Compare Cipla with its competitors · Full profile